Skip to content

Study · Randomized controlled trial · n = 20 · 2011

7 results

GH receptor blocker administration and muscle-tendon collagen synthesis in humans.

Nielsen RH, Doessing S, Goto K, Holm L, Reitelseder S, Agergaard J, Schjerling P, Flyvberg A, Kjaer M

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society16 Apr 2011Cited by 6 (Europe PMC)

PMID21498100 (opens in a new tab)DOI10.1016/j.ghir.2011.03.006 (opens in a new tab)PepBankPUB-21498100
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy young men, pegvisomant did not affect tendon collagen synthesis versus placebo.

    In plain wordsIn healthy young men, pegvisomant did not change tendon collagen synthesis compared with placebo.

    Peptide
    Pegvisomant
    Outcome
    No significant changeTendon collagen synthesis
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Pegvisomant supplementation had no effect on collagen synthesis in tendon and skeletal muscle, nor was muscle myofibrillar protein synthesis affected.
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy young men, pegvisomant did not affect skeletal muscle collagen synthesis versus placebo.

    In plain wordsIn healthy young men, pegvisomant did not change muscle collagen synthesis compared with placebo.

    Peptide
    Pegvisomant
    Outcome
    No significant changeSkeletal muscle collagen synthesis
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Pegvisomant supplementation had no effect on collagen synthesis in tendon and skeletal muscle, nor was muscle myofibrillar protein synthesis affected.
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy young men, pegvisomant did not affect muscle myofibrillar protein synthesis versus placebo.

    In plain wordsIn healthy young men, pegvisomant did not change muscle protein synthesis compared with placebo.

    Peptide
    Pegvisomant
    Outcome
    No significant changeMuscle myofibrillar protein synthesis
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Pegvisomant supplementation had no effect on collagen synthesis in tendon and skeletal muscle, nor was muscle myofibrillar protein synthesis affected.
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy young men, pegvisomant did not affect skeletal muscle IGF-I mRNA expression versus placebo.

    In plain wordsIn healthy young men, pegvisomant did not change muscle IGF-I gene expression compared with placebo.

    Peptide
    Pegvisomant
    Outcome
    No significant changeMuscle IGF-I mRNA expression
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Similarly, pegvisomant supplementation had no effect on mRNA expression of IGF-I and collagen in skeletal muscle.
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy young men, pegvisomant did not affect skeletal muscle collagen mRNA expression versus placebo.

    In plain wordsIn healthy young men, pegvisomant did not change muscle collagen gene expression compared with placebo.

    Peptide
    Pegvisomant
    Outcome
    No significant changeMuscle collagen mRNA expression
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Similarly, pegvisomant supplementation had no effect on mRNA expression of IGF-I and collagen in skeletal muscle.
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy young men, pegvisomant decreased serum IGF-I by 20% from baseline (p<0.01).

    In plain wordsIn healthy young men, pegvisomant lowered IGF-I by 20% from baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF-I
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Measurements

    IGF-I reduction
    20%
    reported result

    Source sentences

    Summary
    Pegvisomant decreased serum IGF-I by 20% (p<0.01) and serum IGFBP-3 by 10% (p<0.05).
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy young men, pegvisomant decreased serum IGFBP-3 by 10% from baseline (p<0.05).

    In plain wordsIn healthy young men, pegvisomant lowered IGFBP-3 by 10% from baseline.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGFBP-3
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    5 mg/day · 2 weeksAs given in this study (human).

    Measurements

    IGFBP-3 reduction
    10%
    reported result

    Source sentences

    Summary
    Pegvisomant decreased serum IGF-I by 20% (p<0.01) and serum IGFBP-3 by 10% (p<0.05).
    1 context sentence
    Summary · context
    20 healthy young males completed the study.InterventionThe participants were randomised to 2 weeks of GH receptor blocker supplementation (pegvisomant, 5 mg/day, n=9) or placebo (n=11).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.